Close Menu

BMS

Tempus has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new cancer biomarkers.

Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

The company aims to use the methylation technology from its multi-cancer screening assay to detect minimal residual disease in early-stage cancer patients.

The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.

Led by a group of 10 biopharmaceutical firms, the project will use Olink's proteomic technology to look at participants' plasma levels of roughly 1,500 proteins.

Translational informatics company Paradigm4's new Reveal: SingleCell app is built on its core SciDB platform that supports fast querying of large multiomic datasets.

Therapy was most effective in patients with a diverse baseline repertoire of T cell receptors and an associated expansion of singleton clones during treatment.

Formerly the data analytics division of CTCA, Vidence is supporting an immuno-oncology trial for BMS as it looks to grow its network of hospital partners.

The partners will use ReviveMed's AI-driven platform to better understand mechanisms of immunotherapy response and resistance in cancer patients.

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.